from ASHEcon at http://bit.ly/2XnNPzU on February 28, 2019 at 10:40PM In an effort to encourage participation by underrepresented communities, the American Society of Health Economics (ASHEcon) jointly with the National Institute of Aging (NIA) funded Center on the Demography and Economics of Health and Aging at Stanford University are offering up to twenty scholarships aimed […]
from Google Alert at http://bit.ly/2TjWlAV on February 28, 2019 at 09:14PM … grew at double the rate of total spending between 2002 and 2016,” said Stefan Gildemeister, the state health economist, in a statement. “For many …
from Google Alert at http://bit.ly/2ISHBES on February 28, 2019 at 09:14PM The well-known health economist, who’s tracked issues like ACA coverage expansion, was named the university’s first associate vice provost for …
from Separating Hyperplanes at http://bit.ly/2NxBa94 on February 28, 2019 at 04:35PM (This meme generator was inspired by this) Bailey text… Motte text…
from OHE News at http://bit.ly/2H7yoGq on February 28, 2019 at 04:29PM In this OHE Seminar Briefing, Dr Steven Pearson, President of ICER, sets out ICER’s early experiences of using HTA to assess gene therapy in the US, setting out four primary challenges.
from RAND Research Topic: Health and Health Care at http://bit.ly/2GVGvH1 on February 28, 2019 at 04:12PM American Indian/Alaska Native adolescents in this study used alcohol or other drugs at rates similar to those found in national surveys and rates of risky sexual behavior were also comparable to national data.
from THCB at http://bit.ly/2NxSRW0 on February 28, 2019 at 04:04PM By JESSICA DaMASSA, WTF HEALTH How can understanding the underlying social risks impacting patient populations improve health outcomes AND save health plans some serious per-member-per-month costs? You’re probably familiar with the concept of ‘Social Determinants of Health’ (SDOH) but Dr. Trenor Williams and his team […]
from AcademyHealth Blog at http://bit.ly/2UdGiBF on February 28, 2019 at 03:01PM AcademyHealth Members Publish Research on Substance Use Treatment, Health Policy Recommendations, and More The January issue of Health Affairs featured several studies authored by AcademyHealth members. Members contributed research to a wide range of pressing issues including substance use and treatment, payment and costs, […]
from feed/http://bit.ly/1sYYZLQ at http://bit.ly/2H7yoGq on February 28, 2019 at 02:53PM In this OHE Seminar Briefing, Dr Steven Pearson, President of ICER, sets out ICER’s early experiences of using HTA to assess gene therapy in the US, setting out four primary challenges.
from tHEORetically Speaking: The HealthEconomics.Com Blog at http://bit.ly/2IKmh4v on February 28, 2019 at 02:32PM The Institute for Clinical and Economic Review’s (ICER) decision to do reports on a drug’s value over time is one that “addresses a pressing issue,” according to Jason Shafrin, a health care economist. Value and estimated value are dynamic variables that […]
from News at http://bit.ly/2H7yoGq on February 28, 2019 at 02:07PM In a new OHE Seminar Briefing, Dr Steven Pearson, President of the Institute for Clinical and Economic Review (ICER), discusses early experiences of using HTA to assess Gene Therapy, setting out four challenges. First, uncertainty about clinical effectiveness makes it difficult for ICER to suggest […]
from Market Design at http://bit.ly/2Tsd5pP on February 28, 2019 at 01:24PM The NY Times has the story: Embryo ‘Adoption’ Is Growing, but It’s Getting Tangled in the Abortion Debate "As evangelical Christians, Paul and Susan Lim believe that life begins at conception. So when they decided to have a third child, in vitro fertilization was […]
from Google Alert at http://bit.ly/2EkvbjT on February 28, 2019 at 12:35PM Presenter: Zeynep Or, Research Director, The Institute for Research and Information in Health Economics. Contact: iHEA ihea@healtheconomics.org …
from Google Alert at http://bit.ly/2T6zsBt on February 28, 2019 at 12:35PM … with increasingly important aspects of demonstrating a product’s value, including patient-reported outcomes (PROs) and health economics
from iDSI at http://bit.ly/2Tp2HyQ on February 28, 2019 at 12:04PM As India moves towards the achievement of Universal Health Coverage (UHC), finding robust and evidence-based answers to the challenges of defining which services should be publicly funded, for whom and how, becomes increasingly important. The introduction of ‘Modicare’, the nascent health insurance scheme announced out […]
from HCHE News at http://bit.ly/2BVy62a on February 28, 2019 at 11:59AM Im Rahmen einer feierlichen Zeremonie überreiche Bundesgesundheitsminister Jens Spahn am 27. Februar den neuen und wiedernannten Mitgliedern des Sachverständigenrats Gesundheit, darunter HCHE-Direktor Professor Jonas Schreyögg, die Ernennungsurkunden. Anschließend trafen sich die Mitglieder zur konstituierenden Sitzung und nutzen diese, um den ersten Vorsitzenden (Allgemeinmediziner Prof. […]
from Journal of Health Economics at http://bit.ly/2Ejrlr6 on February 28, 2019 at 10:43AM Publication date: Available online 28 February 2019 Source: Journal of Health Economics Author(s): Paolo Li Donni Abstract This paper investigates the relationship between self-reported health and material hardship among older Americans. Differently from income-based measures, material hardship provides a more specific description […]
from Health Economics at http://bit.ly/2T6V80w on February 28, 2019 at 08:47AM Abstract We use the 2006 relaxation of constraints on patient choice of hospital in the English NHS to investigate the effect of hospital competition on dimensions of efficiency including indicators of resource management (admissions per bed, bed occupancy rate, proportion of day cases, and […]
from Healthcare Economist at http://bit.ly/2BXduXb on February 28, 2019 at 08:03AM Seven CEOs from large pharmaceutical firms were brought before Congress today. And they got an earful from both Demogratic and Republican Congressmen. The executives were critique for selling too many opioids. They were critiqued for legal manuevers to extend brand name drugs’ patent life. […]
from Google Alert at http://bit.ly/2tFbE8L on February 28, 2019 at 02:46AM Research Fellows – Health economics / Epidemiology | University of Basel | For academic university jobs around the world, including lecturer jobs, …
from Google Alert at http://bit.ly/2H3yBdA on February 28, 2019 at 02:46AM … 2Global Evidence Value and Access (GEVA), Ipsos Healthcare, San Francisco, CA, USA; 3Worldwide Health Economics and Outcomes Research, …
from Google Alert at http://bit.ly/2tI5hle on February 28, 2019 at 02:46AM Min Amy Guo, who had been executive director of the Health Economics and Outcomes Research Group at Novartis, filed the whistle-blower lawsuit in …
from Google Alert at http://bit.ly/2H3yzlY on February 28, 2019 at 02:46AM Health policy Health economics Hospitals Health reform Medicare Private health insurance Private hospitals Federal election 2019 Advancing …
from Google Alert at http://bit.ly/2tEwZz8 on February 28, 2019 at 02:46AM Patient visits that don’t result in drug prescriptions or other treatment may seem costly or unnecessary from a health economics perspective, the …
from Google Alert at http://bit.ly/2H3yxdQ on February 28, 2019 at 02:46AM … but instead of assigning the project to Guo’s team—she headed the company’s Health Economics and Outcomes Research Group—it was given to …
from Google Alert at http://bit.ly/2tIsSCe on February 28, 2019 at 02:46AM “It packages a lot of what we already do in the region, such as health economics with St. Augustine Campus in Trinidad and Tobago; chronic disease …
from Google Alert at http://bit.ly/2H4PULv on February 28, 2019 at 02:46AM … Sequencing with our portfolio of tissue based and liquid biopsy products aimed at improving clinical insight, speed of results and health economics.”.
from Google Alert at http://bit.ly/2tEff79 on February 28, 2019 at 02:46AM Health economics and outcomes researchers have recommended the inclusion of nonclinical value assessments into HEOR such as a treatment’s …
from Google Alert at http://bit.ly/2H3ytL8 on February 28, 2019 at 02:46AM … state, according to Jeff Bechtel, senior vice president of health economics and policy for the Hospital and Healthsystem Association of Pennsylvania, …
from Health Economics at http://bit.ly/2H761rL on February 28, 2019 at 02:46AM Summary This article identifies information asymmetries and the corresponding problem of overtreatment as a possible source of prevention and health disparities when patients differ with respect to their health risk. It analyzes preventive health behavior (primary prevention) and preventive health‐care utilization (secondary prevention) in […]
from Google Alert at http://bit.ly/2tEiA62 on February 27, 2019 at 10:37PM Access to care, overcrowding, emergency service, critical care, wait times, ambulance service and the economics of health care cannot be ignored.
from The Conversation – health economics at http://bit.ly/2H23jUF on February 27, 2019 at 09:00PM Premium subsidies encourage Australians to take out and keep private health insurance. Shutterstock This is part of a major series called Advancing Australia, in which leading academics examine the key issues facing Australia in the lead-up to the 2019 federal election […]
from PharmacoEconomics – Open at http://bit.ly/2EfJENN on February 27, 2019 at 06:13PM The second Key Point for Decision Makers, which reads:
from PharmacoEconomics – Open at http://bit.ly/2T5WoAO on February 27, 2019 at 06:13PM Abstract Background Dofetilide is a class III antiarrhythmic drug indicated for the conversion and maintenance of normal sinus rhythm in symptomatic patients with atrial fibrillation/atrial flutter. Delay in initiation of dofetilide therapy may increase the duration of hospitalization from two nights to three […]
from PharmacoEconomics – Open at http://bit.ly/2Eg6N2N on February 27, 2019 at 06:13PM
from PharmacoEconomics – Open at http://bit.ly/2T2lLUo on February 27, 2019 at 06:13PM Abstract Objectives The aim of this study was to assess direct health costs in children with pertussis aged 0–9 years who were vaccinated, partially vaccinated, and unvaccinated during childhood, and to assess the association between pertussis costs and pertussis vaccination in Catalonia (Spain) in […]
from PharmacoEconomics – Open at http://bit.ly/2Ehi7vr on February 27, 2019 at 06:13PM Abstract Background In Australia, the reimbursement of botulinum neurotoxin-A (BoNT-A) on the Pharmaceutical Benefits Scheme for the treatment of moderate to severe spasticity of the upper limb following a stroke (PSS-UL) is restricted to four treatment cycles per upper limb per lifetime. This […]
from PharmacoEconomics – Open at http://bit.ly/2T7YVLb on February 27, 2019 at 06:13PM Abstract Time trade-off (TTO) is an established method in health economics to elicit and value individuals’ preferences for different health states. These preferences are expressed in the form of health-state utilities that are typically used to measure health-related quality of life and calculate […]
from PharmacoEconomics – Open at http://bit.ly/2EfzHjE on February 27, 2019 at 06:13PM Abstract Background This study’s purpose was to assess the minimal important difference (MID) for the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM–AGHD), a patient-reported outcome measure assessing growth hormone deficiency (GHD) impacts. The measure was demonstrated to have adequate psychometric measurement properties, and […]
from PharmacoEconomics – Open at http://bit.ly/2T3Kp6R on February 27, 2019 at 06:13PM Abstract Background Disease progression and acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF) are associated with high morbidity and mortality. They usually require a visit to a specialist or a general practitioner (GP) in less severe cases or hospitalisation in more severe […]
Health Econ Bot 
You must be logged in to post a comment.